Klivira
Request demo

Optimizing Medicare Fasenra Prior Authorization Workflows

Navigating the complexities of Medicare Fasenra prior authorization is critical for ensuring timely patient access to this essential therapy. Klivira streamlines the process across Original Medicare and Medicare Advantage plans.

For revenue cycle directors and prior authorization coordinators, managing specialty drug approvals like Fasenra under Medicare presents distinct challenges. Understanding the varied submission channels and policy requirements across Part B, Part D, and Medicare Advantage is key to minimizing denials and improving operational efficiency.

Understanding Fasenra in the Medicare Context

Fasenra (benralizumab) is an interleukin-5 (IL-5) receptor alpha antagonist indicated for the add-on maintenance treatment of severe eosinophilic asthma in patients aged 12 years and older. As a high-cost specialty biologic, Fasenra is frequently targeted for prior authorization across various payer types, including Medicare, to ensure medical necessity and appropriate utilization.

Navigating Medicare Prior Authorization Channels for Fasenra

The pathway for Medicare Fasenra prior authorization depends significantly on the specific Medicare program the patient is enrolled in. Original Medicare (Parts A and B) has a limited scope for prior authorization, with submissions routing through Medicare Administrative Contractors (MACs). In contrast, Medicare Advantage (Part C) and Part D plans, administered by private insurers, typically feature more expansive prior authorization requirements.

Original Medicare (Part B) Prior Authorization Considerations

  • For Fasenra, typically administered in an outpatient setting and covered under Medicare Part B, prior authorization is less common but can apply in specific scenarios.
  • Where required, submissions are routed through the responsible MAC for the provider's jurisdiction. Klivira's MAC-aware routing supports per-jurisdiction submission specifics.
  • Key MAC contractors include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.
  • Coverage determinations are guided by National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) published by the MACs.

Medicare Advantage and Part D Prior Authorization for Fasenra

Medicare Advantage (MA) plans (Part C) and Medicare Part D plans (pharmacy benefit) are operated by commercial insurers. These plans administer their own utilization management programs, which typically include prior authorization, step therapy, and quantity limits for specialty drugs like Fasenra, based on their CMS-approved formularies and clinical criteria. Klivira connects directly to these private payer portals and associated PBMs to streamline submissions.

Klivira's Approach to Medicare Fasenra Prior Authorization

Klivira automates the submission process for Medicare Fasenra prior authorization by integrating directly with EMRs and connecting to both MAC-specific channels and private payer portals. Our platform applies NCD/LCD-aware policy logic for Original Medicare and adapts to the diverse formulary and medical policy requirements of Medicare Advantage and Part D plans, reducing manual effort and accelerating approval timelines.

Policy Access and Utilization Management for Fasenra

Accessing accurate and current utilization management policies is crucial. For Original Medicare Part B, coverage for Fasenra is governed by CMS National Coverage Determinations (NCDs) and MAC-specific Local Coverage Determinations (LCDs). Medicare Advantage and Part D plans rely on their proprietary medical policies and formularies, which must align with CMS guidelines. Klivira's comprehensive policy library helps ensure submissions meet current payer requirements.

Frequently asked questions

Is Fasenra always subject to prior authorization under Medicare?

Prior authorization for Fasenra is not universally required across all Medicare programs. While Original Medicare (Part B) has limited PA scope, Medicare Advantage (Part C) and Part D plans frequently require prior authorization for specialty medications like Fasenra, often alongside step therapy or quantity limit protocols.

Which Medicare contractors handle Fasenra prior authorizations for Original Medicare?

For Original Medicare (Part B) prior authorizations, submissions for Fasenra are handled by the Medicare Administrative Contractors (MACs) responsible for your jurisdiction. These include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas, each managing specific geographic regions and services.

How does Klivira manage Fasenra PA submissions for both Original Medicare and Medicare Advantage?

Klivira employs a dual-path approach. For Original Medicare, we route submissions through the appropriate MAC-jurisdiction channels, applying NCD/LCD-aware policy logic. For Medicare Advantage and Part D plans, we connect directly to the specific private payer portals and PBMs, adapting to their unique formularies and medical policies to automate Fasenra prior authorization.

What are the typical turnaround times for Medicare Fasenra prior authorizations?

Turnaround times for Medicare Fasenra prior authorizations vary. For Original Medicare, specific PA programs have defined timeframes. For Medicare Advantage and Part D plans, timeframes are set by the private insurers, generally adhering to regulatory requirements. The CMS-0057-F rule primarily impacts Medicare Advantage and managed care plans, not Traditional Medicare.

Can Klivira help with Fasenra prior authorizations for Medicare Part D plans?

Yes, Klivira supports Fasenra prior authorizations for Medicare Part D plans. Since Part D plans are administered by private commercial insurers, Klivira's platform integrates with these payers and their associated Pharmacy Benefit Managers (PBMs) to automate the submission of necessary documentation and clinical information.

Related coverage

Other fasenra prior authorization by payer

Other fasenra prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo